Liquid Biopsy and Lung Cancer

Area of Science:

• Oncology
• Molecular Diagnostics
• Genomics

Background:

• Non-small cell lung cancer (NSCLC) treatment selection depends on biomarkers like EGFR, ALK, ROS-1, and PD-L1.
• Tissue biopsy is the standard for biomarker identification but can be invasive and challenging.
• Liquid biopsy, analyzing circulating tumor DNA (ctDNA) from plasma, provides a noninvasive alternative for biomarker detection.

Purpose of the Study:

• To review methodologies for analyzing plasma-derived ctDNA in NSCLC patients.
• To highlight the advantages and challenges of liquid biopsy for biomarker identification in NSCLC.
• To emphasize the importance of sensitive and specific technologies for reliable ctDNA analysis.

Main Methods:

• Review of current literature on ctDNA analysis techniques for NSCLC.
• Focus on pre-analytical considerations for plasma sample processing.
• Discussion of technologies for high-sensitivity and specificity ctDNA detection.

Main Results:

• Liquid biopsy offers a less invasive method for detecting NSCLC biomarkers compared to tissue biopsy.
• Low ctDNA yield is a significant challenge, necessitating highly sensitive analytical methods.
• Validation of pre-analytical steps is crucial to minimize false-positive and false-negative results.

Conclusions:

• Plasma-derived ctDNA analysis is a promising noninvasive tool for NSCLC biomarker identification.
• Technological advancements are crucial for overcoming the limitations of low ctDNA yield.
• Standardized and validated methodologies are essential for accurate and reliable ctDNA-based diagnostics in NSCLC.